Intrinsic Value of S&P & Nasdaq Contact Us

Assembly Biosciences, Inc. ASMB NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
59/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$40.00
+34.2%

Assembly Biosciences, Inc. (ASMB) reported total assets of $257.59M and total liabilities of $50.84M for quarter ending 2025-12-31, resulting in total equity of $206.75M.

The company held $248.11M in cash and short-term investments. Total debt stood at $2.63M, with net debt of $-55.82M. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 5.22, indicating strong short-term liquidity.

Criteria supported by this page:

  • HEALTH (100/100, Pass) — Debt-to-Equity of 0.01, current ratio of 5.22 — balance sheet is strong
  • MOAT (50/100) — Total assets $257.59M and equity $206.75M support the company's competitive scale
  • VALUE (90/100) — Debt-to-Equity 0.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 59/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
59/100
SG Score
View full scorecard →
VALUE
90/100
Price-to-Earnings & upside
→ Valuation
FUTURE
64/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
Proven by this page
~
MOAT
50/100
Proven by this page
GROWTH
100/100
→ Income
INCOME
10/100
→ Income
Assembly Biosciences, Inc. Balance Sheet History
Metric Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Total Assets $257.59M$240M$80.78M$99.02M
Total Liabilities $50.84M$57.3M$62.68M$71.88M
Total Debt $2.63M$2.76M$2.88M$3.02M
Cash & Investments $248.11M$232.56M$74.98M$91.03M
Total Stockholders Equity $206.75M$182.7M$18.1M$27.13M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message